Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

pembrolizumab 30 Cisplatin 20 Carboplatin 20 Paclitaxel 18 Dexamethasone 15 Pemetrexed 13 Nivolumab 13 Ipilimumab 12 Fluorouracil 11 Cyclophosphamide 11 Gemcitabine 10 Trastuzumab 9 Docetaxel 9 Cytarabine 9 daratumumab 8 atezolizumab 8 Rituximab 8 Capecitabine 8 Lenalidomide 7 Doxorubicin 7 zanubrutinib 6 Prednisone 6 Daunorubicin 6 Bortezomib 6 venetoclax 5 trametinib 5 nilotinib 5 ibrutinib 5 fludarabine 5 dabrafenib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Has announcements × melflufen × Clear all

NCT02963493 2022-11-22

HORIZON

Oncopeptides AB

Phase 2 Completed

157 enrolled 26 charts 1 FDA

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡